Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12193909 | 0.91 | CYP4F2 (0.48) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL16986998 | 0.88 | PKM (0.49) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL3970403 | 0.88 | PKM (0.49) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL2443534 | 0.87 | PKM (0.48) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL4129353 | 0.87 | PKM (0.48) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL1958618 | 0.87 | PKM (0.48) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL21963889 | 0.85 | PKM (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL7309006 | 0.85 | USP2 (0.43) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL15437724 | 0.85 | PKM (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL23390562 | 0.84 | NR1H2 (0.42) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION INC (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2024249950-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2023235618-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| CN-111454188-A | Cyclopropylamines as L SD1inhibitors | 因赛特公司 | 2020-07-28 | — | — | CN | disclosed |
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090264466-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264466-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264466-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | PKM 478/4885USP2 2522/4885SMN1; SMN2 252/4885 |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | PKM 1859/4885USP2 422/4885SMN1; SMN2 2689/4885 |
| US-20090264466-A1 | Certain Chemical Entities, Compositions and Methods | MYLK, MYH2, MYH10 | PKM 433/4885USP2 2629/4885SMN1; SMN2 262/4885 |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | MEN1, MLLT1, MSI2 | PKM 3271/4885USP2 3835/4885SMN1; SMN2 2354/4885 |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | PKM 1859/4885USP2 422/4885SMN1; SMN2 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.